High-throughput screening of a 100,000-compound library for inhibitors of influenza a virus (H3N2)

Journal of Biomolecular Screening

Volumn 13, Issue 9, 2008, Pages 879-887

  Severson, William E ^a   McDowell, Michael ^a   Ananthan, Subramaniam ^a   Chung, Dong Hoon ^a   Rasmussen, Lynn ^a   Sosa, Melinda I ^a   White, E Lucile ^a   Noah, James ^a   Jonsson, Colleen B ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Antivirals; High throughput screening; HTS; Influenza

Indexed keywords

ANILIDE; ANTIVIRUS AGENT; ARB 06 001447; ARB 06 003174; ARB 06 011087; ARB 06 015735; ARB 06 018302; ARB 06 023109; ARB 06 039422; ARB 06 039665; ARB 06 046310; ARB 06 047279; ARB 06 060912; ARB 06 061324; ARB 06 066995; ARB 06 067081; ARB 06 069269; ARB 06 070333; ARB 06 072422; ARB 06 076399; ARB 06 089154; ARB 06 094955; ARB 06 100287; ARB 06 100378; BENZOTHIAZINE DERIVATIVE; RIBAVIRIN; SULFONAMIDE; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SELECTIVITY; HIGH THROUGHPUT SCREENING; INFLUENZA VIRUS A H3N2; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; AUTOMATION; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DOGS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; INFLUENZA A VIRUS, H3N2 SUBTYPE; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; RIBAVIRIN; VIRUS REPLICATION;

INFLUENZA A VIRUS;

EID: 53649101495     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057108323123     Document Type: Article

References (22)

1. Lamb RA, Krug RM: Orthomyxoviridae: the viruses and their replication. In Fields BN, Knipe DM, Howley PM (eds): Fundamental Virology. Philadelphia: Lippincott-Raven, 1996: 605-647.
2. Thompson WW, Shay DK, Weintraub E., Brammer L., Bridges CB, Cox NJ,, et al. Influenza-associated hospitalizations in the United States. JAMA 2004 ; 292: 1333-1340.
3. Thompson WW, Shay DK, Weintraub E., Brammer L., Cox N., Anderson LJ,, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003 ; 289: 179-186.
4. Ford SM, Grabenstein JD: Pandemics, avian influenza A (H5N1), and a strategy for pharmacists. Pharmacotherapy 2006 ; 26: 312-322.
5. Webby RJ, Webster RG: Are we ready for pandemic influenza ? Science 2003 ; 302: 1519-1522.
6. Morens DM, Fauci AS: The 1918 influenza pandemic: insights for the 21st century. J Infect Dis 2007 ; 195: 1018-1028.
7. Rogers DE, Louria DB, Kilbourne ED: The syndrome of fatal influenza virus pneumonia. Trans Assoc Am Physicians 1958 ; 71: 260-273.
8. De Clercq E.: Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 2006 ; 5: 1015-1025.
9. Fiore AE, Shay DK, Haber P., Iskander JK, Uyeki TM, Mootrey G.,, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep 2007 ; 56 (RR- 6). 1-54.
10. Fernandez-Larsson R., O'Connell K., Koumans E., Patterson JL: Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction. Antimicrob Agents Chemother 1989 ; 33: 1668-1673.
11. Toltzis P., Huang AS: Effect of ribavirin on macromolecular synthesis in vesicular stomatitis virus-infected cells. Antimicrob Agents Chemother 1986 ; 29: 1010-1016.
12. Eriksson B., Helgstrand E., Johansson NG, Larsson A., Misiorny A., Noren JO,, et al. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother 1977 ; 11: 946-951.
13. Wray SK, Gilbert BE, Knight V.: Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res 1985 ; 5: 39-48.
14. Romanova J.: The fight against new types of influenza virus. Biotechnol J 2006 ; 1: 1381-1392.
15. Bright RA, Shay DK, Shu B., Cox NJ, Klimov AI: Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006 ; 295: 891-894.
16. Luke C., Subbarao K.: Vaccines for pandemic influenza. Emerg Infect Dis 2006 ; 12: 66-72.
17. Severson WE, Shindo N., Sosa M., Fletcher T. III, White EL, Ananthan S.,, et al. Development and validation of a high-throughput screen for inhibitors of SARS CoV and its application in screening of a 100,000-compound library. J Biomol Screen 2007 ; 12: 33-40.
18. Noah JW, Severson W., Noah DL, Rasmussen L., White EL, Jonsson CB: A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals. Antiviral Res 2007 ; 73: 50-59.
19. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999 ; 4: 67-73.
20. Matrosovich M., Matrosovich T., Garten W., Klenk HD: New low-viscosity overlay medium for viral plaque assays. Virol J 2006 ; 3: 63.
21. Lipinski CA, Lombardo F., Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 1997 ; 23: 3-25.
22. Ertl P., Rohde B., Selzer P.: Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 2000 ; 43: 3714-3717.